Genscript Biotech (1548) Aktienübersicht
Die Genscript Biotech Corporation, eine Investment-Holdinggesellschaft, ist in der Herstellung und dem Verkauf von biowissenschaftlichen Forschungsprodukten und -dienstleistungen in den Vereinigten Staaten von Amerika, Europa, Festlandchina, Europa, im asiatisch-pazifischen Raum und international tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
1548 Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Genscript Biotech Corporation Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | HK$16.10 |
| 52-Wochen-Hoch | HK$19.40 |
| 52-Wochen-Tief | HK$10.36 |
| Beta | 0.85 |
| 1 Monat Veränderung | 32.84% |
| 3 Monate Veränderung | 16.25% |
| 1 Jahr Veränderung | -9.75% |
| 3 Jahre Veränderung | -20.69% |
| 5 Jahre Veränderung | -52.79% |
| Veränderung seit IPO | 1,119.70% |
Aktuelle Nachrichten und Updates
1548: New Expression Platform Will Support Future Cell Therapy Upside
Analysts have made a small adjustment to their price target for Genscript Biotech to HK$17.68. This reflects updated views on the company’s fair value, discount rate, revenue growth, profit margin and future P/E assumptions.1548: European mRNA Buildout And Cell Therapy Data Will Support Future Upside
Analysts have made a very small upward adjustment to Genscript Biotech's fair value estimate, moving the target from about HK$17.67 to roughly HK$17.67. They refreshed assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect current views on the business.Recent updates
1548: New Expression Platform Will Support Future Cell Therapy Upside
Analysts have made a small adjustment to their price target for Genscript Biotech to HK$17.68. This reflects updated views on the company’s fair value, discount rate, revenue growth, profit margin and future P/E assumptions.1548: European mRNA Buildout And Cell Therapy Data Will Support Future Upside
Analysts have made a very small upward adjustment to Genscript Biotech's fair value estimate, moving the target from about HK$17.67 to roughly HK$17.67. They refreshed assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect current views on the business.1548: European mRNA Expansion Will Support Future Upside Potential
Analysts have kept their HK$17.67 price target for Genscript Biotech broadly unchanged, with only slight tweaks to the discount rate and future P/E assumptions shaping this latest narrative update. What's in the News GenScript plans to put amendments to its fourth amended and restated memorandum and articles of association to a shareholder vote at the AGM on June 5, 2026, and proposes adopting a fifth amended and restated version of these governing documents (Key Developments).1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have trimmed their price target for Genscript Biotech to about HK$17.67 from roughly HK$18.56, citing slightly lower fair value estimates and a modestly reduced future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its mRNA platform and reinforcing Europe as a core part of its integrated R&D and production network (Key Developments).1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have slightly adjusted their view on Genscript Biotech, trimming the implied fair value from about HK$18.95 to around HK$18.56 as they fine tune assumptions on revenue growth, profit margin and future P/E levels. What's in the News Genscript opened its first European mRNA production site in Delft, the Netherlands, adding gene design, synthesis, vector engineering, IVT mRNA production, GenCap mRNA capping, UTR optimization and formulation support within a single facility (Key Developments).
Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins
Catalysts About Genscript Biotech Genscript Biotech is a global biotech group focused on gene to protein research tools, biologics CRDMO services and industrial enzyme products. What are the underlying business or industry changes driving this perspective?1548: European mRNA Expansion Will Support Ongoing Upside Potential
Analysts have trimmed their HK$ price target on Genscript Biotech from about HK$22.12 to around HK$18.95, citing updated assumptions for slower revenue growth, a higher profit margin profile, and a lower future P/E multiple in their models. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its global mRNA platform with end to end capabilities that include gene design, vector engineering, IVT mRNA production, GenCap mRNA capping technology, UTR optimization, and formulation support (Key Developments).1548: Higher Future P/E Assumptions Will Support Ongoing Upside Potential
Analysts have adjusted their HK$ price target for Genscript Biotech to reflect updated views on discount rate, long term profit margins and a higher assumed future P/E multiple. This has resulted in a modest recalibration of fair value rather than a wholesale shift in the investment case.1548: Slightly Lower Future P/E Will Still Support Attractive Upside Potential
Analysts have trimmed their price target on Genscript Biotech to reflect a slightly lower assumed future P/E multiple, while keeping fair value broadly unchanged at about HK$22.12. They cite fine tuning of discount rate and margin assumptions rather than any major shift in the core outlook.1548: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have trimmed their fair value estimate for Genscript Biotech from $23.52 to $22.12, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Genscript Biotech held an Analyst/Investor Day, giving the market a closer look at its business, capital plans, and the assumptions that feed into analyst models (Key Developments).Unpleasant Surprises Could Be In Store For Genscript Biotech Corporation's (HKG:1548) Shares
With a median price-to-sales (or "P/S") ratio of close to 5.5x in the Life Sciences industry in Hong Kong, you could be...Is Genscript Biotech Corporation (HKG:1548) Trading At A 44% Discount?
Key Insights Genscript Biotech's estimated fair value is HK$30.13 based on 2 Stage Free Cash Flow to Equity Genscript...We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings
The market for Genscript Biotech Corporation's ( HKG:1548 ) shares didn't move much after it posted weak earnings...Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Despite a sharp decline in consensus revenue growth forecasts and a substantial jump in future P/E, analysts have raised Genscript Biotech's fair value estimate from HK$21.61 to HK$23.01. What's in the News GenScript Biotech launched a new global brand platform, "Scripting Possibilities," alongside a refreshed visual identity and expanded marketing initiatives to drive growth and strengthen global brand presence.Genscript Biotech Corporation's (HKG:1548) 28% Price Boost Is Out Of Tune With Revenues
Genscript Biotech Corporation ( HKG:1548 ) shares have continued their recent momentum with a 28% gain in the last...At HK$18.16, Is It Time To Put Genscript Biotech Corporation (HKG:1548) On Your Watch List?
Genscript Biotech Corporation ( HKG:1548 ), might not be a large cap stock, but it saw a significant share price rise...Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
Genscript Biotech Corporation ( HKG:1548 ) shares have retraced a considerable 27% in the last month, reversing a fair...Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump
Genscript Biotech Corporation ( HKG:1548 ) shares have had a really impressive month, gaining 27% after a shaky period...Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Genscript Biotech is HK$19.29 based on 2 Stage Free Cash Flow to Equity...Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
It's not a stretch to say that Genscript Biotech Corporation's ( HKG:1548 ) price-to-sales (or "P/S") ratio of 2.9x...Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Genscript Biotech Corporation ( HKG:1548 ), might not be a large cap stock, but it received a lot of attention from a...After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Genscript Biotech Corporation ( HKG:1548 ) shares have had a really impressive month, gaining 44% after a shaky period...Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Unfortunately for some shareholders, the Genscript Biotech Corporation ( HKG:1548 ) share price has dived 28% in the...A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
Key Insights The projected fair value for Genscript Biotech is HK$14.11 based on 2 Stage Free Cash Flow to Equity With...Is Genscript Biotech (HKG:1548) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Genscript Biotech Corporation ( HKG:1548 ) shareholders are no doubt pleased to see that the share price has bounced...Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Genscript Biotech Corporation ( HKG:1548 ) shareholders that were waiting for something to happen have been dealt a...Is Genscript Biotech (HKG:1548) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is Genscript Biotech (HKG:1548) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Aktionärsrenditen
| 1548 | HK Life Sciences | HK Markt | |
|---|---|---|---|
| 7D | 21.8% | -1.8% | 1.4% |
| 1Y | -9.8% | 12.2% | -3.8% |
Rendite im Vergleich zur Industrie: 1548 unter dem Niveau der Branche Hong Kong Life Sciences , die im vergangenen Jahr eine Rendite von 12.2% erzielte.
Rendite vs. Markt: 1548 hinter dem Markt Hong Kong zurück, der im vergangenen Jahr eine Rendite von -3.8 erzielte.
Preisvolatilität
| 1548 volatility | |
|---|---|
| 1548 Average Weekly Movement | 11.3% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in HK Market | 16.4% |
| 10% least volatile stocks in HK Market | 3.7% |
Stabiler Aktienkurs: Der Aktienkurs von 1548 war in den letzten 3 Monaten im Vergleich zum Hong Kong -Markt volatil.
Volatilität im Zeitverlauf: 1548Die wöchentliche Volatilität (11%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der Hong Kong Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2002 | 6,165 | Sherry Shao | www.genscript.com |
Die Genscript Biotech Corporation, eine Investment-Holding, ist in der Herstellung und dem Verkauf von biowissenschaftlichen Forschungsprodukten und Dienstleistungen in den Vereinigten Staaten von Amerika, Europa, Festlandchina, Europa, im asiatisch-pazifischen Raum und international tätig. Das Unternehmen ist in drei Segmenten tätig: Biowissenschaftliche Dienstleistungen und Produkte, Biologics Development Services und Industrielle Produkte der Synthetischen Biologie. Das Segment Biowissenschaftliche Dienstleistungen und Produkte bietet Produkte und Dienstleistungen in verschiedenen Kategorien an, darunter Gensynthese, Oligonukleotid-Synthese, Peptid-Synthese, Protein-Engineering, Antikörper-Entwicklung sowie biowissenschaftliche Geräte und Verbrauchsmaterialien wie molekulare Diagnostik-Tools und Genom-Editing-Materialien für biologische Studien, pharmazeutische und Arzneimittelforschung, Krankheitsdiagnostik und Impfstoffe, Landwirtschaft, Umweltstudien und die Lebensmittelindustrie.
Genscript Biotech Corporation's Grundlagenzusammenfassung
| 1548 grundlegende Statistiken | |
|---|---|
| Marktanteil | HK$35.21b |
| Gewinn(TTM) | -HK$4.18b |
| Umsatz(TTM) | HK$7.52b |
Ist 1548 zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| 1548 Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$959.53m |
| Kosten der Einnahmen | US$406.32m |
| Bruttogewinn | US$553.20m |
| Sonstige Ausgaben | US$1.09b |
| Gewinn | -US$532.83m |
Zuletzt gemeldete Gewinne
Dec 31, 2025
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.24 |
| Bruttomarge | 57.65% |
| Nettogewinnspanne | -55.53% |
| Schulden/Eigenkapital-Verhältnis | 7.1% |
Wie hat sich 1548 auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/24 11:31 |
| Aktienkurs zum Tagesende | 2026/07/24 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Genscript Biotech Corporation wird von 12 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Wai Chak Yuen | Daiwa Securities Co. Ltd. |